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Effect of intensive treatment on diabetic nephropathy in patients with
type I diabetes. We evaluated the long-term effect of an intensive
treatment of diabetic nephropathy (anti-hypertensive drugs, low protein
diet, multiple insulin injections to achieve a good metabolic control) on
glomerular filtration rate (GFR) and albumin excretion rate (AER).
Fourteen type I diabetic patients (mean age 45 9.5 years, mean duration
of diabetes 23.5 7.3 years, 8 males/6 females) with glomerular filtration
rate <70 ml/min1/1.73 m2 and albumin excretion rate >30 g/min were
treated intensively for 36 months. This intensive treatment consisted of
multiple insulin injections, antihypertensive therapy with ACE inhibitors
and a low-protein diet (0.8 g/kg body wt/day.) Renal function was
evaluated as GFR and AER. HbA1c mean value decreased significantly
from 8.7 0.8% to 6.5 0.5% (P < 0.0002). GFR rose from 58 12
ml/min'/1.73 m2 to 84 11 ml/min1/1.73 m2 (P < 0.0008). AER
decreased from 208 ig/min (range: 73 to 500) to 63.8 jgImin (range 15 to
180; P < 0.05). Systolic and diastolic blood pressure decreased respectively
from 144 26 mm Hg to 120 15 mm Hg and from 89 9 mm Hg to
75 8 mm Hg (P < 0.01). We obtained a rise of GFR and a reduction of
proteinuria after three years of this treatment. We suggest that this
intensive treatment in all patients with early stage diabetic nephropathy
may be effective in slowing the progression to renal failure.
Diabetic nephropathy is defined by a progressive decline in
glomerular function until end-stage renal failure and is character-
ized by persistent albuminuria >300 mg/24 hr, decline in glomer-
ular filtration rate and often raised blood pressure [1—4]. The
presence of proteinuria is not simply a marker of the extent of
glomerular damage but proteinuria per se may contribute to renal
lesions. This complication which is the single most important
cause of renal failure, affects approximately 30 to 40% of insulin-
dependent diabetic patients 151 and is the main cause of death
(30%) in these patients. Mean survival rate after the development
of persistent proteinuria is about seven years [6] in the absence of
any treatment. For this reason it is necessary to identify therapeu-
tic schemes which may prevent the evolution of diabetic nephrop-
athy. In fact each of the following treatments, that is, improve-
ment of metabolic control [7, 8], careful control of blood pressure
[9—11] as well as a low-protein intake [12, 131, was able by itself to
slow the decline of renal function and to reduce the proteinuria.
Thus we designed a pilot preliminary study to evaluate the
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long-term effect of an intensive treatment on glomerular filtration
rate and albuminuria, consisting of an improvement of metabolic
control, an antihypertensive therapy with angiotensin converting
enzyme (ACE) inhibitors and a low-protein diet.
Methods
We have studied the effects of a long-term period of intensive
treatment (36 months) in fourteen type I diabetic patients with
impaired renal function, who were fully informed of the experi-
mental nature of the study. Inclusion criteria were glomerular
filtration rate (GFR) <70 ml min1 1.73 m2 and persistent
albumin excretion rate (AER) >30 Lg/min. Strict metabolic
control was achieved through multiple (that is, 3 to 4 daily) insulin
injections; the dosage was adjusted according to glucose self-
monitoring (4 times daily). The long-term intensive treatment also
included antihypertensive therapy with the ACE inhibitors enala-
pril (10 to 20 mg/day) or captopril (25 to 50 mg/day) and a
low-protein diet containing 32 9 Kcal day/kg with 0.8 g/kg body
wt/day of protein, of which 30% were vegetable proteins.
The clinical characteristics of the subjects are given in Table 1.
None of the participants was affected by other renal or systemic
disease or took any drug during the study. One of these patients
experienced one episode of myocardial ischemia at the end of the
second year of treatment.
Urea excretion was used to calculate protein intake from the
nitrogen content of the urea and an estimated value of non-urea
nitrogen of 31 mg kg day [14]. Assuming a constant nitrogen
balance, nitrogen intake = nitrogen content of urinary urea plus
non-urea nitrogen, and protein intake (g/day) = nitrogen intakeS
6.25 [15].
The adhesion to the diet was assessed by analysis of three-day
weighed food records collected every six months. GFR was
determined as already described [16]. To evaluate GFR a single
intravenous bolus injection of 51CrEDTA 1 j.Cu/kg (Sorin, Sal-
luggia, Italy) was calibrated and made up to 10 ml with NaCI
(0.9%), which was then administered 90 minutes after breakfast.
Blood plasma samples were taken at 5, 10, 20, 30, 44, 50, 60, 80,
120, 180, 240 and 360 minutes after the injection. The results were
standardized for 1.73 m2 body surface area, using the patients
surface area at the start of the study. On the day of the test the
patients received their usual insulin doses; their glycemic levels
were checked every hour during the test and additional insulin
units were administered if glucose levels were found to be higher
than 160 mg/dl. During the test the patients were in the supine
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position and were asked to avoid smoking. GFR was measured as
the clearance of the isotopes under the assumption that all the
tracer is excreted and that the only route of excretion is renal.
Thus the total amount of tracer excreted will be equal to the
quantity injected. Measurement techniques for plasma clearance
may be classified as follows:
(1) Double exponential analysis utilizes all blood samples to
obtain the two slopes A and A2.
(2) Monoexponential analysis utilizes only later plasma samples
taken at 80, 120, 180, 240 and 360 minutes.
(3) The method from value distribution measurement utilizes
only the sample taken at 180 minutes.
We preferred to use double exponential analysis because it is
very reliable. In our laboratory the values of GFR in normal
subjects range from 80 to 130 ml min1 1.73 m2. The accuracy
of this method, which is commonly used as a reliable technique to
assess renal function is demonstrated by a correlation index with
renal insulin clearance of 97%. Blood urea nitrogen was deter-
mined by Berthelot reaction, serum and urinary creatinine were
measured by a modification of the Jaffé method with alkaline
nitrate [17], and glycated hemoglobin (HbA1c) by the HPLC
method. AER was evaluated in three overnight urine collections
by radioimmunoassay (Albumin DA, Tecnogenetics, Italy). Sys-
tolic and diastolic blood pressure were evaluated twice with a
Random-Zero mercury sphygmomanometer by the same ob-
server. During the treatment period systolic and diastolic blood
pressure and body weight were monitored every month, HbA1c
levels every two months and AER every six months. GFR and
creatinine clearance were measured every year.
Statistical analysis
Data are expressed as the mean SEM except for AER which
is shown as median and range values. Paired t-test was used to
compare the differences before and at the end of the study. All
calculations were made using Statview 512 (Apple Computer
Inc.). Differences were considered significant at P < 0.05 (two
tailed).
Results
One patient (N = 14) showed no compliance to the treatment
protocol, namely low-protein diet and antihypertensive therapy.
In this patient we observed a progressive decrease in renal
function with a dramatic reduction in GFR (from 70 ml/min1/
0
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Fig. 2. Average course of glomendar filtration rate (GFR) before and during
the intensive treatment. *p < 0.0005; < 0.0008).
1.73 m2 to 40 ml/min'/1.73 m2) and an increase in AER (from
1 g/liter to 5 g/liter) despite the improvement of the HbA1c value
(from 9.2% to 6.7%).
In the other 13 patients the HbA1c mean value was significantly
lowered from 8.7 0.8% to 6.5 0.5% (P < 0.0002; Fig. 1) after
three years of intensive treatment. A significant improvement of
GFR was observed in these patients: 58 12 ml/min 1/173 m2 at
the beginning of the study, 72 24 ml/min 1/1.73 m2 after one
year, 87 15 ml/mint/1.73 m2 after two years (P < 0.0005) and
84 11 after three years of treatment (P < 0.0008) (Fig. 2).
Figure 3 shows GFR values for each patient during the study
period. Creatinine clearance was unchanged after this period:
61 12 ml/min versus 65 14 ml/min (P = NS). AER decreased
from 208 jg/min (range 73 to 500) to 91.3 Wmin (range 36 to
300) after one year of treatment, to 60 g/min (range 15 to 136)
after two years and to 63.8 tg/min (range 15 to 180) at the end of
the study (P < 0.05; Fig. 4). Four patients, with macroalbumin-
uria, had only microalbuminuria at the end of the study.
Table 1. Clinical characteristics of 14 patients with diabetic
nephropathy
Age years 45 9.5
Duration of diabetes years 23.5 7.3
Sex 8M/6 F
BMI kg/1.73 m2 25 1.4
W/H ratio 0.8 0.1
Insulin doses 41.3 8.7
BUN mg/dl 19.6 4
Creatinine mgldl 1.08 0.22
Creatinine clearance mI/mm 61 12
SBP mm Hg 144 26
DBP mm Hg 89±9
Abbreviations are: BMI, body mass index; W/H, waist/hip; SBP, systolic
blood pressure; DBP, diastolic blood pressure.
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Fig. 1. Mean HbA1c values before and during 36 months of intensive
treatment (*P < 0.0002).
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ACE-inhibitor treatment resulted in a reduction of systolic (144
26 mm Hg vs. 120 15 mm Hg) and diastolic blood pressure
(89 9 mm Hg vs. 75 8 mm Hg; P < 0.01; Fig. 5). No change
was observed in blood urea nitrogen and creatinine plasma levels
during the period of intensive treatment.
The effect of the same treatment protocol is currently being
studied in three additional patients: preliminary results show that
after a one year follow-up GFR improved from 67 12 ml/min'/
1.73 m2 to 109 15 ml/min1/1.73 m2; AER reduced from 90
g/min to 41.6 p.glmin, and HbA1c is significantly lowered from
7.7 0.3% to 6.8 0.5%.
Discussion
The aim of our study has been to evaluate the effect of three
associated treatments (anti-hypertensive therapy, low-protein
diet, multiple insulin injections) on the progression of diabetic
nephropathy. Because each one of these treatments has been
shown to reduce microalbuminuria and progressive GFR decline
we deemed it not ethical to have a control group without any
treatment.
Previous studies have shown that each type of intervention per
se is able to reduce albumin excretion rate and the rate of monthly
decline of renal function.
Time, months
Fig. 4. Albumin excretion rate (AER) in microalbuminuric (A) and mac-
roalbuminuric (B) patients before and during the intensive treatment.
Several studies found a decreased impairment of GFR and a
reduction in urinary albumin excretion in diabetic patients with
nephropathy treated with a low-protein diet (0.6 g/kg) [12, 13].
In our study the reduction of the daily protein intake from
1.35 g/kg to 0.80 g/kg was attained through an increase in
the amounts of bread, pasta, legumes and fruit, and a reduction
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Fig. 3. A. GFR in 13 patients before and during the intensive treatment.
B. Means of GFR in the same patients at the start and at the end of the
study.
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Fig. 5. Mean blood systolic (SBP, ) and diastolic pressure (DBP,)
before and after two years of antihypertensive treatment (*P < 001).
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of the amounts of cheese, meat and fish. This modification
decreased the quantity of animal proteins and was quite compat-
ible with Italian nutritional habits; this made compliance to the
diet easier for the patients. A low protein intake protected against
the progressive sclerosis of functioning glomeruli in experimental
diabetic nephropathy [18, 19]; however, the relevance of these
animal studies to human renal disease is unknown. On the other
hand, dietary protein is known to exert profound effects on the
renin-angiotensin-aldosteron system. In fact, a low-protein diet
per se suppresses this system [20, 21], ameliorating renal function.
We didn't find any significant change of serum creatinine and
creatinine clearance after three years. These parameters are
unreliable indicators of kidney function in renal disease. When
patients are on a low-protein diet, there is a variation in the
creatinine pool and metabolism which is independent from the
changes in GFR [12]. Furthermore, the measurements of creati-
nine clearance can overestimate GFR in patients with severe renal
insufficiency, while variability in urine collections may result in
poor reproducibility of these measurements [22].
Other studies have evaluated the effect of long-term antihyper-
tensive treatments on the progression of diabetic nephropathy [9,
23, 24]. Many authors have performed different studies comparing
ACE inhibitors with a-blockers or with calcium antagonists [10,
25—29] and all of these studies have shown that early antihyper-
tensive treatment per se was able to slow the decline of renal
function in diabetic nephropathy and dramatically improve the
survival rates [30, 31]. ACE inhibitor therapy also has an anti-
proteinuric effect independent from the effect on systemic blood
pressure [32—34]; this may be due either to diminished glomerular
capillary idraulic pressure or to enhanced intrinsic selectivity of
the glomerular barrier wall. In fact antihypertensive treatment
with ACE inhibitors is able to improve both size and charge
selective properties of glomerular capillary filtration barrier [35].
There is a strong correlation between level of microalbuminuria
and rate of decline in GFR [36]. It has been demonstrated that a
pronounced decrease in proteinuria after the start of antihyper-
tensive treatment predicts a more benign course of renal disease
in IDDM patients [23, 24]. Other mechanisms proposed to explain
the improvement of renal function induced by ACE inhibitors are:
(1) a block of mesangial cell growth [37] through the inhibition of
the production of angiotensin II, which is a growth factor; and
(2) the inactivation of kininase II, a kinin degrading enzyme,
resulting in accumulation of bradykinin in the renal circulation
[38, 39].
In agreement with the above-mentioned reports our results
show that treatment with ACE inhibitors induced a decrease of
albumin excretion rate and a regression from macroalbuminuria
to microalbuminuria in four of the patients. Furthermore, the
activity of angiotensin converting enzyme which was elevated in
our patients before the treatment was completely suppressed by
ACE inhibitors (data not shown).
The effect of metabolic control on the development and pro-
gression of diabetic nephropathy in type 1 (insulin-dependent)
diabetic patients has been widely studied with conflicting results:
in the Oslo study [40] and in the Steno study [7, 41] the reduction
of GFR was shown to be slower in patients with early nephropathy
treated with CSII than in those treated with conventional therapy.
The DCCT [42] has shown that in the intensive therapy group the
risk of albuminuria was reduced by 56% and that very few patients
developed nephropathy. Recently it has been shown that the
improvement of blood glucose control retards the development of
structural changes in early diabetic nephropathy [43]. In patients
with diabetic nephropathy Nyberg, Blohmè and Norden [44]
found a significant correlation between HbA1c levels and rate of
decline in GFR, while other studies [3, 45] found no relationship
between the two parameters. On the other hand, Viberti et al [46]
showed that the progression of diabetic nephropathy was not
reversed by the improvement of glycemic control. In our study
good metabolic control, obtained with multiple insulin injections,
improved renal function only in association with a low-protein
diet and antihypertensive treatment. In fact we observed that the
only patient who showed no compliance to diet and to antihyper-
tensive therapy had a progressive decline in GFR in spite of good
metabolic control.
The pathogenesis of diabetic nephropathy is not fully under-
stood and a variety of mechanisms have been hypothesized
(genetic predisposition, hyperglycemia per se, non-enzymatic gly-
cosilation, hyperfiltration). Thus it is possible that a multiple
therapeutic intervention, such as the one employed in our study,
can act on the different pathogenetic mechanisms to delay or to
change the natural evolution of diabetic nephropathy.
In conclusion, we suggest that a combination of low-protein
diet, antihypertensive treatment and good metabolic control in
patients with early alterations of renal function (proteinuria and
reduction of GFR) can postpone the progression to renal failure.
A longer follow-up is mandatory to verify if this treatment is able
to preserve the kidney from renal failure.
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